GlassScriptPhysician profile
Sharon L Goldstein
NPI 1609849587
$4,032.49
in general payments reported to CMS, 2019-2025
15 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $218 · 2021: $242 · 2022: $840 · 2023: $296 · 2024: $1,280 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,063 · Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,062.50 |
| Food and Beverage | $651.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $1,862.48 | 2020-2024 | Precisetumor, Myrisk |
| Medtronic USA, INC. | $819.16 | 2019 | |
| Hologic INC | $696.50 | 2022 | |
| Seagen INC. | $120.83 | 2021 | |
| Stryker Corporation | $118.94 | 2025 | Molli, Spy-Phi System |
| Merck Sharp & Dohme LLC | $93.69 | 2022-2024 | Keytruda |
| Tesaro, INC. | $90.30 | 2019 | |
| Leica Microsystems INC. | $48.15 | 2019 | |
| Davol INC. | $37.35 | 2020 | |
| Ethicon US, LLC | $30.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.40 | 2019 | |
| Tactile Systems Technology INC | $23.27 | 2023 | Entre Plus, Flexitouch Plus |
| Baudax Bio INC. | $22.79 | 2020 | |
| Mentor Worldwide LLC | $19.48 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Novo Nordisk INC | $18.66 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.